Show simple item record

 
dc.contributorDepartament de Salut
dc.contributor.authorRey-Reñones, Cristina
dc.contributor.authorBaena-Diez, José Miguel
dc.contributor.authorAguilar-Palacio, Isabel
dc.contributor.authorMiquel, Cristina
dc.contributor.authorGrau, Maria
dc.date.accessioned2022-09-20T12:34:59Z
dc.date.available2022-09-20T12:34:59Z
dc.date.issued2021-10-09
dc.identifier.citationRey-Reñones C, Baena-Díez JM, Aguilar-Palacio I, Miquel C, Grau M. Type 2 Diabetes Mellitus and Cancer: Epidemiology, Physiopathology and Prevention. Biomedicines. 2021 Oct 9;9(10):1429.
dc.identifier.issn2227-9059
dc.identifier.urihttp://hdl.handle.net/11351/8230
dc.descriptionType-2 diabetes mellitus; Epidemiology; Cancer
dc.description.abstractIndividuals with type 2 diabetes mellitus are at greater risk of developing cancer and of dying from it. Both diseases are age-related, contributing to the impact of population aging on the long-term sustainability of health care systems in European Union countries. The purpose of this narrative review was to describe, from epidemiological, pathophysiological and preventive perspectives, the links between type 2 diabetes mellitus and the most prevalent cancers in these patients. Multiple metabolic abnormalities that may occur in type 2 diabetes mellitus, particularly obesity, could explain the increased cancer risk. In addition, the effectiveness of drugs commonly used to treat type 2 diabetes mellitus (e.g., metformin and thiazolidinediones) has been broadly evaluated in cancer prevention. Thus, a better understanding of the links between type 2 diabetes mellitus and cancer will help to identify the contributing factors and the pathophysiological pathways and to design personalized preventive strategies. The final goal is to facilitate healthy aging and the prevention of cancer and other diseases related with type 2 diabetes mellitus, which are among the main sources of disability and death in the European Union and worldwide.
dc.language.isoeng
dc.publisherMDPI
dc.relation.ispartofseriesBiomedicines;9(10)
dc.rightsAttribution 4.0 International
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.sourceScientia
dc.subjectDiabetis no-insulinodependent
dc.subjectOncologia - Malalties - Prevenció
dc.subject.meshDiabetes Mellitus, Type 2
dc.subject.meshNeoplasms
dc.subject.mesh/complications
dc.titleType 2 Diabetes Mellitus and Cancer: Epidemiology, Physiopathology and Prevention
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.3390/biomedicines9101429
dc.subject.decsdiabetes mellitus tipo II
dc.subject.decsneoplasias
dc.subject.decs/complicaciones
dc.relation.publishversionhttps://doi.org/10.3390/biomedicines9101429
dc.type.versioninfo:eu-repo/semantics/publishedVersion
dc.audienceProfessionals
dc.contributor.authoraffiliation[Rey-Reñones C] Research Support Unit-Camp de Tarragona, Catalan Institute of Health (ICS), Tarragona, Spain. IDIAP Jordi Gol, Catalan Institute of Health (ICS), Barcelona, Spain. School of Medicine and Health Sciences, Universitat Rovira i Virgili, Reus, Spain. [Baena-Díez JM] IDIAP Jordi Gol, Catalan Institute of Health (ICS), Barcelona, Spain. La Marina Primary Care Center, Catalan Institute of Health (ICS), Barcelona, Spain. [Aguilar-Palacio I] Research Group in Health Services of Aragon, (GRISSA) IIS Aragón, University of Zaragoza, Zaragoza, Spain. [Miquel C] Department of Medicine, University of Barcelona, Barcelona, Spain. [Grau M] Serra Húnter Fellow, Department of Medicine, University of Barcelona, Barcelona, Spain. Biomedical Research Consortium in Epidemiology and Public Health (CIBERESP), Barcelona, Spain. IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain
dc.identifier.pmid34680546
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record